Wright Christopher I
Known title: DirectorCIK: 0001838503
Associated companies
Transaction History
| ALKS | ▼ Sell | Open Market | 2,000 | $90K | 6/12/2026 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,475 | $55K | 5/21/2026 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 6,142 | — | 5/21/2026 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 3,301 | — | 6/8/2025 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 793 | $25K | 6/8/2025 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 8,013 | — | 5/31/2025 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,924 | $59K | 5/31/2025 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 6,104 | — | 6/29/2024 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,465 | $35K | 6/29/2024 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 3,301 | — | 6/8/2024 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 793 | $19K | 6/8/2024 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,430 | $43K | 7/7/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 5,957 | — | 7/7/2023 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 777 | $25K | 6/8/2023 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 90 | $3K | 6/8/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 3,236 | — | 6/8/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 373 | — | 6/8/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Baird Highlights Growth Potential for Alkermes plc (ALKS)
Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.
Baird Highlights Growth Potential for Alkermes plc (ALKS). Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.